US EditionSymptoms Timeline and Outcomes in Amyotrophic Lateral Sclerosis Using Artificial Intelligence
10 Articles
10 Articles
Progresses in the therapies for some forms of Sla of genetic origin. The appeal to the institutions: "Resolve the inconsistencies of the new Nomenclatore of the prosthetic assistance: the spare parts for the electric wheelchairs and platform mounts"
Symptoms timeline and outcomes in amyotrophic lateral sclerosis using artificial intelligence
Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative motor neuron disease. Although an early diagnosis is crucial to provide adequate care and improve survival, patients with ALS experience a significant diagnostic delay. This study aimed to use real-world data to describe the clinical profile and timing between symptom onset, diagnosis, and relevant outcomes in ALS. Retrospective and multicenter study in 5 representative hospitals …
Silent and devastating, amyotrological lateral sclerosis (ELA) is a rare disease that affects motor neurons responsible for body movements. As the first signs are discreet, diagnosis usually occurs too late when the patient has lost some of its ability to move, [...]
Preclinical Study Results Funded by AriSLA Published in the Journal 'Cell Death and Differentiation'
Milan, 20/06/2025 – Our cells are able to promptly repair the multiple damages suffered every day by the DNA present in them, through a process of response to damage (the ‘DNA Damage Response’, DDR). In the motor neurons of patients affected by Amyotrophic Lateral Sclerosis, this cellular response does not work effectively, contributing to neurodegeneration. Two studies on ALS supported by AriSLA (DDRNA&ALS; DDR&ALS) and conducted at the Institu…
On the occasion of World Amyotrophic Lateral Sclerosis (ALS) Day, the Catalan Foundation of ALS Miquel Valls is relaunching the campaign “Make a gesture for ALS”, an initiative that this 2025 reaches its tenth anniversary. The objective remains the same: to raise awareness, mobilize and promote solidarity with people affected by this neurodegenerative disease. The campaign […] The entry The Catalan Foundation of ALS Miquel Valls celebrates the t…
There are three patients in the ALS Unit of the La Paz Hospital in Madrid, with almost 300 patients, about to begin a new treatment whose funding has just been approved in public health, tofersén, a drug that could preserve neuronal function and slow the progression of a disease that, until now, has never been stopped. On the occasion of World Day of Amyotrophic Lateral Sclerosis (ELA), on 21 June, we deepened in the tofersen, a therapy directed…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
